Latest News

Pharmaceutical Merck files Keytruda for lung cancer, eyes first-line niche

Merck files Keytruda for lung cancer, eyes first-line niche

Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.

Pharmaceutical FDA takes unusual stance on ALS drug

FDA takes unusual stance on ALS drug

The FDA asked private biotech Genervon to release all available clinical trial data for its experimental ALS treatment.

Pharmaceutical Conflict-of-interest rules spur $23M investment

Conflict-of-interest rules spur $23M investment

Schools spent $23 million to bring conflict-of-interest policies in line with regulations aimed at ensuring federally funded research is unbiased.

Pharmaceutical

J&J to pay $63M in Motrin case

A Massachusetts court upheld a 2013 decision that the drugmaker failed to provide sufficient risk information for Children's Motrin.

Pharmaceutical Five things for pharma marketers to know: Monday, April 20

Five things for pharma marketers to know: Monday, April 20

Teva eyes Mylan takeover; Keytruda shown to improve survival, shrink tumors in melanoma; ADHD abuse may follow grads into workforce.

Features Editor's Desk: And the researchers go wild

Editor's Desk: And the researchers go wild

Apple's ResearchKit could accelerate the pace at which industry approaches start-ups building products in the patient-facing part of health tech

Pharmaceutical Five things for pharma marketers to know: Friday, April 17

Five things for pharma marketers to know: Friday, April 17

The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down

Agency Bob Finkel launches 'agency alternative'

Bob Finkel launches 'agency alternative'

Kane & Finkel co-founder Bob Finkel launched a healthcare consultancy that will seek out limited-commitment projects.

Legal/Regulatory

Amgen motion to delay Neupogen biosimilar denied

Amgen's attempt to delay Zarxio was denied by a US District Court, which said the argument was speculative.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.